Literature DB >> 31636906

Dermatofibrosarcoma protuberans associated with a hamartochondroma of the lung: Diagnostic discussion of a pulmonary nodule.

Hicham Harmouchi1, Lakranbi Marouane1,2, Rabiou Sani1, Issoufou Ibrahim1, Ouadnouni Yassine1,2, Smahi Mohammed1,2.   

Abstract

Dermatofibrosarcoma protuberans is a malignant tumor of the soft tissue which is characterized by local recurrence with an exceptional metastasize, and for this reason, patients with dermatofibrosarcoma protuberans require a long-term follow-up. This clinical case presents a 41-year-old patient, with no pathological history, who has a malignant tumor of the chest wall, with a pulmonary nodule, which appears on the chest computed tomography scan like a well-rounded parenchymal nodule measuring 15 mm in diameter. This case was discussed in the multidisciplinary meeting which concluded that it is a dermatofibrosarcoma protuberans with metastasis of the lung. In the context of these data, it is thought that the pulmonary nodule is of metastatic origin according to the decision of the multidisciplinary meeting, while the final diagnosis was a hamartochondroma, which is a benign tumor of the lung. The interest of this clinical case is to discuss the possible diagnoses of the pulmonary nodule in the context of malignant wall tumor.
© The Author(s) 2019.

Entities:  

Keywords:  Dermatofibrosarcoma; diagnosis; hamartochondroma; nodule

Year:  2019        PMID: 31636906      PMCID: PMC6783656          DOI: 10.1177/2050313X19878050

Source DB:  PubMed          Journal:  SAGE Open Med Case Rep        ISSN: 2050-313X


Introduction

Dermatofibrosarcoma protuberans is a rare chest wall malignant tumor which most frequently affects the dermis and subcutis[1] and is recognized by the local recurrence. Its incidence represents 0.1% of malignant tumors of soft tissues.[2] Pulmonary hamartochondroma is the most common benign tumor of the lung. The association of the two tumors is not exceptional (benign lung tumor and malignant tumor of the chest wall), but the appearance of the hamartochondroma in the form of a pulmonary nodule has made it possible to present this clinical case for discussion of the diagnosis of this nodule. Is it a metastatic nodule or a nodule of another etiology? Our goal is to answer this question in this manuscript.

Case report

This clinical case presents a 41-year-old patient, with any pathological history, who consults for a tumefaction of the left posterior thoracic wall evolving in a context of conservation of the general state. The clinical examination finds a hard mass, budding, fixed to the deep plane (Figure 1). The patient consulted a dermatologist who performed a biopsy of the mass returning in favor of a dermatofibrosarcoma protuberans. The chest computed tomography (CT) scan objectified in addition to the tumor of the chest wall the presence in the upper left lobe of a well-rounded parenchymal nodule measuring 15 mm in diameter (Figures 2 and 3). Positron emission tomography (PET) scan was not requested because of its unavailability in our region. This case was discussed in the multidisciplinary meeting which concluded that it is a dermatofibrosarcoma protuberans with metastasis of the lung. The decision was to operate the patient. Wide resection of the tumor at 3 cm from its banks was performed, after the patient has benefited of a posterolateral thoracotomy for the pulmonary nodule whose macroscopic appearance has objectified cartilaginous consistency suggestive of a hamartochondroma, and a wedge resection was practiced. Histological study showed tumoral proliferation with fasciculate and storiform architecture. The tumor cells are spindle-shaped with elongated nuclei, increased size, fine chromatin and eosinophilic cytoplasm poorly limited. This proliferation infiltrates the dermis and hypodermis. For the pulmonary nodule, it was a lesion well limited and consists essentially of mature cartilaginous lobules surrounded by fibro-adipose tissue. All that were dissociated by slots were covered with a respiratory type epithelium, cylindrical ciliated and pseudostratified. The follow-up to now is 8 months, without any local recurrence or distant metastasizes.
Figure 1.

Dermatofibrosarcoma protuberans of the left posterior thoracic wall, hard and budding.

Figure 2.

Thoracic CT showed a cutaneous tumor process in the posterior thoracic wall compatible with dermatofibrosarcoma protuberans.

Figure 3.

Thoracic CT in parenchymal window showed pulmonary nodule of the left upper lobe solid measuring 15 mm.

Dermatofibrosarcoma protuberans of the left posterior thoracic wall, hard and budding. Thoracic CT showed a cutaneous tumor process in the posterior thoracic wall compatible with dermatofibrosarcoma protuberans. Thoracic CT in parenchymal window showed pulmonary nodule of the left upper lobe solid measuring 15 mm.

Discussion

The association of dermatofibrosarcoma and pulmonary hamartochondroma is not exceptional on the medical side. In this case, dermatofibrosarcoma protuberans of chest wall was associated with a pulmonary nodule, and the first question which was asked was, “What is the diagnosis of this nodule? Is it a metastatic nodule of the dermatofibrosarcoma protuberans or just a benign nodule?” According to the multidisciplinary committee, the presence of the tumor of the chest wall and the features of the pulmonary nodule (well-rounded nodule, measuring 15 mm), the latter was considered as a metastasis site of the dermatofibrosarcoma protuberans. However, as a result, histological study of this nodule was in favor of a hamartochondroma and a wedge resection was performed. Dermatofibrosarcoma protuberans is a rare tumor, but not exceptional, that has been identified for the first time by Jean Darier and Marcel Ferrand as a real clinical and histological entity.[3] Its tendency to local recurrence requires extensive surgical resection.[4] Therefore, metastasizes to the regional lymph node or distant site (lung, bone, etc.) remain rare and are found in less than 6% of the cases, and for this particularity are classified as a sarcoma of intermediate grade malignancy.[5-10] The basic treatment of dermatofibrosarcoma protuberans remains surgical excision, with margins of 3–5 cm to avoid local recurrence.[11] Radiotherapy is indicated in case of incomplete excision, and chemotherapy is the reference treatment in metastatic cases.[11,12] On the contrary, hamartochondroma is the most frequent lung benign tumor.[13] It is a tumor derived from the peribronchial mesenchymal tissue constituted in an absolute disorder and in variable proportions of cartilage, connective tissue, fat, smooth muscle and respiratory epithelium.[3] The multidisciplinary meeting concluded that the parenchymal nodule is likely a metastasize of the chest wall tumor, since the features of the nodule were not in favor of other etiological orientations. Radiologically, pulmonary hamartochondroma is usually of heterogeneous density, sometimes with a popcorn appearance. In our case, the signs that are in favor of a pulmonary metastasis are especially the presence of the dermatofibrosarcoma protuberans, the solid character of the nodule, with a homogeneous density, without greasy density, and the central character of the nodule. However, the main points are with a benign nodule: the well-defined contours, the absence of local recurrence of dermatofibrosarcoma since the rate of metastasis increases after local recurrence. Also, it must be pointed out that the patient did not benefit from a PET CT to clearly specify the benign or malignant nature of the pulmonary nodule because of the unavailability in our region.

Conclusion

The principle of the management of a pulmonary nodule is to not ignore a malignant nodule at a curable stage, and to not carry out invasive explorations for a benign nodule. In this clinical case, association of dermatofibrosarcoma protuberans with pulmonary hamartochondroma has allowed to discuss the diagnosis of pulmonary nodule that remains generally of variable etiologies.
  11 in total

1.  Dermatofibrosarcoma protuberans.

Authors:  Vassilios A Dimitropoulos
Journal:  Dermatol Ther       Date:  2008 Nov-Dec       Impact factor: 2.851

2.  [Darrier-Ferrand tumor of the anterior chest wall].

Authors:  F Atoini; A Zidane; A Arsalane; H Elkaoui; E H Kabiri
Journal:  Rev Pneumol Clin       Date:  2008-10-25

3.  Dermatofibrosarcoma protuberans: clinical diagnoses and treatment results of 260 cases in China.

Authors:  Hong Cai; Yanong Wang; Jianghong Wu; Yingqiang Shi
Journal:  J Surg Oncol       Date:  2011-08-03       Impact factor: 3.454

4.  Benign tumors of the lung. A ten-year surgical experience.

Authors:  M G Arrigoni; L B Woolner; P E Bernatz; W E Miller; R S Fontana
Journal:  J Thorac Cardiovasc Surg       Date:  1970-10       Impact factor: 5.209

Review 5.  [Clinical characteristics of resected bronchial hamartoma. Study of seven cases].

Authors:  A Zehani-Kassar; A Ayadi-Kaddour; A Marghli; I Ridene; T Kilani; F El Mezni
Journal:  Rev Mal Respir       Date:  2011-04-16       Impact factor: 0.622

Review 6.  Dermatofibrosarcoma protuberans with fibrosarcomatous transformation of the head and neck.

Authors:  Nikolaos Angouridakis; Panagiotis Kafas; Waseem Jerjes; Stefanos Triaridis; Tahwinder Upile; Georgios Karkavelas; Angelos Nikolaou
Journal:  Head Neck Oncol       Date:  2011-02-04

7.  Radiotherapy in the treatment of dermatofibrosarcoma protuberans.

Authors:  Roi Dagan; Christopher G Morris; Robert A Zlotecki; Mark T Scarborough; William M Mendenhall
Journal:  Am J Clin Oncol       Date:  2005-12       Impact factor: 2.339

Review 8.  The role of radiation therapy in the management of dermatofibrosarcoma protuberans.

Authors:  M T Ballo; G K Zagars; P Pisters; A Pollack
Journal:  Int J Radiat Oncol Biol Phys       Date:  1998-03-01       Impact factor: 7.038

Review 9.  Surgical treatment of dermatofibrosarcoma protuberans. A retrospective study of 20 cases with review of literature.

Authors:  M G Smola; H P Soyer; E Scharnagl
Journal:  Eur J Surg Oncol       Date:  1991-10       Impact factor: 4.424

10.  Outcomes of surgery for dermatofibrosarcoma protuberans.

Authors:  C K Chang; I A Jacobs; G I Salti
Journal:  Eur J Surg Oncol       Date:  2004-04       Impact factor: 4.424

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.